June 25, 2015
Menlo Park, CA
Much has happened over the past few months in the area of patent protection in the life sciences area. We are finally seeing implementation (or lack thereof) of the Biologics Price Competition and Innovation Act (BPCIA) provisions, an increased number of IPRs involving pharma and biotech patents, including challenges by hedge funds, and the Federal Circuit’s latest attempt to address joint infringement. Please join Paul Barker, Jonathan Davies, Rob McCauley, and Sanya Sukduang as they address the following topics:
Who Should Attend: General counsel and in-house patent counsel in the life sciences fields with responsibility for/interest in protecting a company’s intellectual property.
MCLE Credit: Finnegan confirms that this activity has been certified for 4.25 hours of California MCLE.
For more information, please contact Finnegan IP Programs
Conference
4th Annual Passport to Proficiency on the Essentials of Hatch-Waxman and BPCIA
October 8-24, 2024
Virtual
Hybrid Conference
2024 Patent Law Institute: Critical Issues & Best Practices
September 30 - October 1, 2024
New York
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.